Once-a-day painkiller aceclofenac injection developed by Venus Remedies has been granted a patent by Indian patent office.
Aceclofenac is a non steroidal anti-inflammatory drug (NSAID) used to relieve acute as well as chronic pain and inflammation in rheumatoid arthritis, osteoarthritis, low back pain, ankylosing spondylitis, dental pain, post traumatic pain, gynecological pain and
With grant of this patent Venus has now 7 national and international patents granted from its kitty of 341 patents, Venus Remedies said in a press statement.
Venus Remedies’ novel formulation based on NDDS (Novel drug delivery system) technology starts its action instantly and gives immediate relief from acute pain.
The once-daily aceclofenac injection will be effective for the next 24 hours as against the conventional daily dose of three injections of diclofenac given every 8 hr.
It not only reduces the number of pricks but also drastically reduces the side effects associated with the use of NSAIDs.
Opioid based products or conventional NSAIDs being used currently for pain management are associated with side effects such as vomiting, nausea, abdominal distress.
Aceclofenac is designed in such a way that the product is never released in super or sub therapeutic zones and hence is highly safe and practically free from side effects.
The most prevalent forms of neuropathic pain in country includes neuralgia/fibromyalgia and lower back pain, with 16.3 million and 15.9 million cases respectively during 2008.
Analgesics (narcotics and non–narcotics) account for 43% of the global pain management market, having generated revenues of $19.9bn in 2007, showing an annual growth of 15.2 %.
Venus Remedies is currently in talks with global pharmaceutical companies of South Asian region for out licensing of once-a-day painkiller aceclofenac injection.
Venus Remedies launched Potentox in Indian market two years back.
Potentox was launched in Indian market on gaining DCGI approva after submitting the data from preclinical and multicentric phase-III clinical trials on more than 300 patients. Potentox has already been used by more than 20,000 patients across India.
Post marketing phase IV studies were also conducted to re-establish the safety of Potentox.
In August, Venus Remedies got another Product Patent for Tobracef from the Companies and Intellectual Property Registration Office (CIPRO), South Africa. Tobracef, which is indicated for the treatment of complicated mixed bacterial infection of acute pulmonary exacerbations, cystic fibrosis, chronic obstructive pulmonary disease, an FDC cephalosporin and aminoglycoside.
Tobracef was launched in July 2008. Tobracef is under process of registration in many regulated and semi – regulated markets.
Venus Remedies India has two manufacturing locations in India and one in Germany. Venus is a contract manufacturer of oncological and cefelosporine injectable products following EU-GMP norms.
In November 2009, Venus Remedies received patents from South Africa for its antibiotic combination product Potentox.
Potentox is a combxnation of a cephalosporin with aminoglycoside indicated for the treatment of hospital acquired pneumonia, community acquired pneumonia and Febrile Neutropenia.
Potentox is the third product of Venus Remedies being granted Companies and Intellectual Property Registration Office (CIPRO) in South Africa after Sulbactomax and Tobracef.
CIPRO’s also also the third patent of Potentox within five months of its first grant in South Korea.
Potentox has potential to reduce the toxicity caused by aminoglycosides and disease condition.WHO data suggest that there are 4.50 million cases of pneumonia, are a leading cause of death and years of life last in South Africa.Pneumonia is fifth leading cause of death in females and seventh major cause of mortality in males.
In Sub-Saharan Africa among HIV-infected patients presenting with a lower respiratory tract infection have confirmed that community-acquired pneumonia is the second cause of death with incidence of pneumonia due to S. pneumonae rising to 34.5 per cent.
In South Africa currently 8 per cent gross domestic product (GDP) is spent on health and more than half of the is amount is channelled into medical insurance schemes that serve the indicates that there is huge gap in demand and supply keeping in view the mortality in African continent.